tbuckley/cabot-search huggingface dataset:
Richard Mead (1673-1754) successor to John Radcliffe
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AN ERUPTIVE FEVER OF UNUSUAL CHARACTERISTICS IN INFANCY AND EARLY CHILDHOOD
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies
Authors: D. C. Skegg
Journal: JAMA (1995)

<h3>Background.</h3> —Although depot medroxyprogesterone acetate (DMPA) (Depo-Provera) has now been approved for marketing as a contraceptive in the United States, there are still unresolved issues about the relation between DMPA and risk of breast cancer. The two substantial case-control studies of this association yielded similar but inconclusive results. Because their designs were compatible, these studies were pooled to obtain more adequate data for analysis. <h3>Design.</h3> —Pooled results from two case-control studies. <h3>Setting.</h3> —New Zealand (entire country), Thailand (three centers), Mexico (one center), and Kenya (one center). <h3>Participants.</h3> —A total of 1768 women with breast cancer and 13905 controls, most of whom were younger than 55 years. <h3>Main Outcome Measure.</h3> —Relative risk (RR) of breast cancer in women who had used DMPA. <h3>Results.</h3> —The RR of breast cancer for women who had ever used DMPA was 1.1 (95% confidence interval [CI], 0.97 to 1.4). There was no increase in risk with increasing duration of use of DMPA, but RR estimates were higher in certain subgroups of women. Further analyses suggested that recent (or current) use was the key factor, with women who had started using DMPA within the previous 5 years estimated to have an RR of 2.0 (95% CI, 1.5 to 2.8). <h3>Conclusions.</h3> —The increased risk of breast cancer observed in recent (or current) users could be due to enhanced detection of breast tumors in women using DMPA or to acceleration of the growth of preexisting tumors. Women who had used DMPA more than 5 years previously had no increase in risk of breast cancer, regardless of their duration of use. (<i>JAMA</i>. 1995;273:799-804)
Abstract 2126: Development of a precision chordoma research program
Authors: Marie Groth, Jana Kress, Matea Hajnic, Joana Marinho, Kevin Mellert, Thomas F. Barth, Peter Möller, Birgit Dreier, Andreas Plückthun, Claudia Scholl, Stefan Fröhling
Journal: Cancer Research (2019)

Abstract Chordomas are malignant tumors of the axial skeleton that originate from remnants of the embryonic notochord. With an incidence of one per million per year, chordoma is a rare disease that accounts for 1-4% of all bone tumors and approximately 20% of primary spinal tumors. As first-line treatment, patients undergo surgical resection followed by adjuvant radiotherapy, whereas most chordomas are resistant to conventional cytotoxic drugs and there are no clinically validated molecular drug targets. To overcome the lack of effective medical treatment and to better understand chordoma biology, we have established a chordoma precision research program. Here, whole-exome or genome and transcriptome sequencing are used to determine mutational landscapes, DNA copy number profiles, and transcriptome changes in chordoma cell lines and patient samples. Additionally, large-scale functional genomic screens and (phospho-)proteomic analyses have been performed in multiple chordoma cell lines to identify new chordoma-specific vulnerabilities. Based on these multilayered datasets, we selected a panel of previously unrecognized candidate chordoma driver genes, which are currently being validated as novel therapeutic targets using genetic and pharmacologic approaches. In addition to this unbiased approach, we seek to inhibit the embryonic transcription factor brachyury, an established driver of chordomagenesis. Although brachyury represents, in principle, a promising therapeutic target, inhibition of transcription factors remains difficult. To circumvent this challenge, we are developing Designed Ankyrin Repeat Proteins (DARPins) that specifically prevent the binding of brachyury to DNA. These DARPins are not only a valuable tool for studying chordomagenesis, but also represent a new class of molecularly targeted agents that might be used for the treatment of chordoma patients. In summary, using multi-omics data, functional genetics, and inhibition of an established chordoma driver, we are working towards a better understanding of chordoma biology and the development of new therapeutic approaches. Updated results of the precision chordoma research program will be presented. Citation Format: Marie Groth, Jana Kress, Matea Hajnic, Joana Marinho, Kevin Mellert, Thomas F. Barth, Peter Möller, Birgit Dreier, Andreas Plückthun, Claudia Scholl, Stefan Fröhling. Development of a precision chordoma research program [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2126.
Incorrect Name
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcome of Patients with IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplants: A Retrospective CIBMTR Study.
Authors: Donna E. Reece, David H. Vesole, Smriti Shrestha, Angela Dispenzieri, Gustavo Milone, Waleska S. Peréz, Mei-Jie Zhang, Parameswaran Hari
Journal: Blood (2008)
Appendectomy for a Non-Shadow-Casting Ureteral Calculus in a Child.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Intravenous Cholesterol Oleate on the Function of the Reticuloendothelial System
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ORIGINAL ARTICLES.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
Authors: Andrea Mayer, Markus Loeffler, Sarah Missel, Roberto Accolla, Yuk Ting Ma, Tanguy Chaumette, Regina Heidenreich, Alfred Königsrainer, Joerg Ludwig, Diego Alcoba, Heiko Schuster, Cecile Gouttefangeas, Greta Forlani, Maria Tagliamonte, Paolo Antonio Ascierto, Antonio Avallone, Marco Borrelli, Hans-Georg Rammensee, Bruno Sangro, Mercedes Iñarrairaegui, Sven Francque, Luisa Vonghia, Stefania Gori, Tony Weinschenk, Carsten Reinhardt, Ulrike Gnad-Vogt, Harpreet Singh, Luigi Buonaguro
Journal: Journal of Hepatology (2020)
Stoke Park Monographs on Mental Deficiency and Other Problems of the Human Brain and Mind. No. I.: The Burden Memorial Volume Dedicated to the Memory of the Late Reverend Harold Nelson Burden, Founder and First Warden of the Incorporation of National Institutions for Persons Requiring Care and Control.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pertussis vaccines. A progress report
Authors: R. Rabinovich
Journal: JAMA (1994)

Since pertussis vaccines were introduced in the 1940s, physicians have recognized their association with adverse events, and this association has continued to the present time. Today we use whole-cell vaccines made up of killed inactivated organisms of<i>Bordatella pertussis</i>that contain a multitude of antigens, some of which induce protection to severe whooping cough. Several of these materials, such as endotoxin, may account for these vaccines' reactogenicity. Commonly reported minor reactions include pain and swelling at the injection site, fever, and vomiting. More worrisome to parents and physicians are episodes of somnolence, febrile seizures, unusual prolonged screaming, and hyporesponsive-hypotonic episodes; yet none of these has been demonstrated to be associated with permanent sequelae.<sup>1</sup>
HYPERTROPHY OF THE HEART.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?
Authors: Marijke Coomans, Linda Dirven, Neil Aaronson, Brigitta Baumert, Martin van den Bent, Andrew Bottomley, Alba Brandes, Olivier Chinot, Corneel Coens, Thierry Gorlia, Ulrich Herrlinger, Florence Keime-Guibert, Annika Malmström, Francesca Martinelli, Roger Stupp, Andrea Talacchi, Michael Weller, Wolfgang Wick, Jaap Reijneveld, Martin J.B. Taphoorn
Journal: Neuro-Oncology (2018)

Symptom management in glioma patients remains a challenge, as patients suffer from various concurrent occurring symptoms. This study aimed to identify symptom clusters and to examine the relation between these symptom clusters and functioning. We prospectively included individual patient data from previously published international randomized controlled trials (RCTs) in glioma patients. Symptom prevalence and level of functioning were assessed with EORTC QLQ-C30 and QLQ-BN20 questionnaires. The magnitude of the associations between symptoms were examined with Spearman correlation coefficients and correlation matrices. Hierarchical cluster analyses (looking at euclidean distances) were performed to identify symptom clusters. Multivariable regression analyses were performed to analyze associations between the symptom clusters and functioning, adjusted for confounding variables. Data of 3595 newly diagnosed glioma patients who completed the questionnaires before randomization indicated that many patients (44%) suffered from 5–10 symptoms simultaneously. The most prevalent symptoms were fatigue, drowsiness and motor dysfunction, experienced by 86%, 59% and 55% of the patients respectively. Five symptom clusters were identified with hierarchical cluster analyses: motor cluster, fatigue cluster, headache cluster, gastrointestinal/seizures cluster and hair loss/itchy skin cluster. Having symptoms in the motor cluster had a clinically relevant and significant negative influence (≥10points difference) on the global health status/quality of life scale, and physical, role, cognitive and social functioning (Beta’s ranged from -10.9 to -18.6, all p<0.001). Similarly, having symptoms in the fatigue cluster had a clinically relevant negative influence on the global health status/quality of life scale, and role and social functioning (Beta’s ranged from -10.7 to -15.5, all p<0.001) CONCLUSIONS: Two symptom clusters, the fatigue and motor cluster, were frequently affected in glioma patients and demonstrated to negatively influence functioning and global quality of life. Implementation of interventions targeting fatigue and motor problems would therefore contribute to improved functioning and quality of life in glioma patients.
Human Rabies—Florida, 1996
Journal: JAMA (1996)

ON FEBRUARY 8, 1996, a 26-year-old man died in a hospital in Naples, Florida, following progressive neurologic deterioration. Rabies had been clinically suspected on the day he was admitted (December 30, 1995) and was confirmed by CDC on January 10, 1996. This report summarizes the investigation of this case by the Florida Department of Health and Rehabilitative Services, Collier County Public Health Unit, which indicated a dog in Mexico as the probable source of exposure. The patient was a citizen of Mexico who entered the United States on December 4, 1995. He sought care from a private physician in Immokalee, Florida, on December 29 because of anxiety, difficulty breathing while speaking, left lower-quadrant abdominal pain, left leg pain, lower back pain, and lethargy. Findings on physical examination included injected conjunctivae, a temperature of 96.3 F (35.7 C), pulse of 112 beats per minute, and rebound tenderness to the abdomen.
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Authors: Helen Gogas, John Ioannovich, Urania Dafni, Catherine Stavropoulou-Giokas, Konstantina Frangia, Dimosthenis Tsoutsos, Petros Panagiotou, Aristidis Polyzos, Othonas Papadopoulos, Alexandros Stratigos, Christos Markopoulos, Dimitrios Bafaloukos, Dimitrios Pectasides, George Fountzilas, John M. Kirkwood
Journal: New England Journal of Medicine (2006)

Immunotherapy for advanced melanoma induces serologic and clinical manifestations of autoimmunity. We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b.
The Distribution of Organs for Liver Transplantation-Reply
Authors: Oscar Bronsther
Journal: JAMA (1994)

<h3>In Reply.</h3> —It is true that one of the authors (T.E.S.) endorsed the original organ distribution plans and in fact wrote them in May 1987 in order to prevent a UNOS default of contract obligation. One plan was for kidneys and the other for extrarenal organs. Disputes within the appointed organ distribution committee had prevented development of the required document. What was used was taken verbatim from two impending publications describing the distribution systems already in place in Pittsburgh.<sup>1,2</sup>The existence of these manuscripts had been made known to UNOS by two colleagues, resulting in the last-minute recruitment of Dr Starzl. The principles of both plans are still embraced by UNOS, but with a changed meaning. Originally, overwhelming weight for liver distribution was given to urgency of need because there is no treatment option comparable with the artificial kidney. "Boutique" liver recipients called in for operation from the 19th
Autologous and aged blood donors
Authors: D. R. Avoy
Journal: JAMA (1987)

<h3>To the Editor.—</h3> In his editorial entitled "Autologous and Aged Blood Donors,"<sup>1</sup>Greenwalt quotes Perkins<sup>2</sup>as saying that the probability of a person needing a transfusion during the permissiblestorage period "has got to be very low." No data are provided. By using existing census data<sup>3</sup>and information about transfusion trends from the study of Friedman et al,<sup>4</sup>a more quantitative estimation of probability may be attempted. The logic is as follows: Approximately 4 million patients undergo transfusion in this country each year. Based on a total population of 236 million, the raw probability would be 1.66% that any individual would receive a transfusion in any year, or about one person in 60. Transfusions are not linearly distributed throughout the population. Persons younger than age 20 years represent 29.8% of the population and only 7.1% of the population receiving transfusions. Only 0.4% of this